MedTrace Logo

Remimazolam TIVA-Flumazenil Antagonism in Short-duration ENT Surgeries

NCT07389798 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 511

Last updated 2026-05-11

No results posted yet for this study

Summary

This study plans to categorize patients who underwent short-duration ENT surgeries with remimazolam TIVA combined with flumazenil antagonism based on whether their intraoperative BIS values were maintained below 60.

Conditions

  • Remimazolam
  • Total Intravenous Anesthesia
  • Bispectral Index

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Aihua Du, Dr · Tongji Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-09
Primary Completion
2026-03-29
Completion
2026-04-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07389798 on ClinicalTrials.gov